Drugs / AT1019
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07285395 | Nov 2025 → Dec 2026 expected | cancer | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AT1019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07285395 ↗ |
| Route | Other | “Receive intratumoral injection of AT1019 within 1 to 2 days after each SBRT session.” NCT07285395 ↗ |